Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/db mice

American Journal of Physiology - Endocrinology and Metabolism

Volumn 288, Issue 3 51-3, 2005, Pages

  Kawasaki, Fumiko ^a   Matsuda, Masafumi ^a   Kanda, Yukiko ^a   Inoue, Hiroshi ^a   Kaku, Kohei ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Adiponectin; Pancreatic cells; Type 2 diabetes mellitus

Indexed keywords

ADIPONECTIN; FATTY ACID; GLUCOSE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CELL COUNT; CELL DAMAGE; CELL FUNCTION; CELL PROTECTION; CELL STRUCTURE; CONTROLLED STUDY; FATTY ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE UTILIZATION; IMMUNOHISTOCHEMISTRY; INSULIN RELEASE; INSULIN SENSITIVITY; MOUSE; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPONECTIN; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CELL COUNT; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; FATTY ACIDS, NONESTERIFIED; GLUCOSE; HYPOGLYCEMIC AGENTS; INSULIN; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; ISLETS OF LANGERHANS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, CELL SURFACE; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 13844262626     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00128.2004     Document Type: Article

References (37)

1. Azen SP, Peters RK, Berkowitz K, Kjos S, Xiang A, and Buchanan TA. TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin Trials 19: 217-231, 1998.
2. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, and Azen SP. Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51: 2796-2803, 2002.
3. Cavaghan MK, Ehrmann DA, and Polonsky KS. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest 106: 329-333, 2000.
4. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, and Laakso M; STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359: 2072-2077; 2002.
5. Coleman DL. Obese and diabetes: two mutant genes causing diabetes-obesity- syndromes in mice. Diabetologia 14: 141-148, 1978.
6. Combs TP, Wagner JA, Berger J, Doebber T, Wang W, Zhang BB, Tanen M, Berg AH, Orahilly S, Savage DB, Chatterjee K, Weiss S, Larson PJ, Gottesdiener KM, Gertz BJ, Charron MJ, Scherer PE, and Moller DE. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARγ agonists: a potential mechanism of insulin sensitization. Endocrinology 143: 998-1007, 2002.
7. DeFronzo RA, Bonadonna RC, and Ferannini E. Pathogenesis of NIDDM: a balanced overview. Diabetes Care 15: 318-368, 1992.
8. Diani AR, Sawada G, Wyse B, Murray FT, and Khan M. Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes. Am J Physiol Endocrinol Metab 286: E116-E122, 2004.
9. Fajans SS, Bell GI, and Polonsky KS. Mechanisms of disease: molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med 345: 971-980, 2001.
10. Finegood DT, McArthur MD, Kojwang D, Thomas MJ, Topp BG, Leonard T, and Buckingham RE. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 50: 1021-1029, 2001.
11. Fruebis O, Tsao T, Javorschi S, Ebbets-Reed D, Erickson MRS, Yen FT, Bihain BE, and Lodish HF. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Nad Acad Sci USA 98: 2005-2010, 2001.
12. Fujiwara T, Horikoshi H, Yazaki Y, and Kadowaki T. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101: 1354-1361, 1998.
13. Higa M, Zhou YT, Ravazzola M, Baetens D, Orci L, and Unger RH. Troglitazone prevents mitchondrial alterations, β-cell destruction, and diabetes in obese prediabetic rats. Proc Natl Acad Sci USA 96: 11513-11518, 1999.
14. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, and Matsuzawa Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20: 1595-1599, 2000.
15. Hotta K, Funahashi T, Bodkin NB, Ortmeyer HK, Arita Y, Hansen BC, and Matsuzawa Y. Circulating concentrarions of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in Rhesus monkeys. Diabetes 50: 1126-1133, 2001.
16. Hummel KP, Dickie MM, and Coleman DL. Diabetes, a new mutation in the mouse. Science 153: 1127-1128, 1966.
17. Kaku K, Province M, and Permutt MA. Genetic analysis of obesity-induced diabetes associated with limited capacity to synthesize insulin in C57BL/KS mice: evidence for polygenic control. Diabetologia 32: 636-643, 1989.
18. Kharroubi I, Rasschaert J, Eizirik DL, and Cnop M. Expression of adiponectin receptors in pancreatic β cells. Biochem Biophys Res Commun 312: 1118-1122, 2003.
19. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, and Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393-403, 2002.
20. Kosaka K, Kuzuya T, Akanuma Y, and Hagura R. Increase in insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatment. Diabetologia 18: 23-28, 1980.
21. Leahy JL. Impaired β-cell fonction with chronic hyperglycemia: "over-worked β-cell" hypothesis. Diabetes Rev 4: 298-319, 1996.
22. Lee GH, Proenca R, Montez JM, Carroll KM, Darvishzadeh JG, Lee JI, and Friedman JM. Abnormal splicing of the leptin receptor in diabetic mice. Nature 379: 632-635, 1996.
23. Lee Y, Hirose H, Ohneda M, Johnson JH, McGarry JD, and Unger RH. β-Cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-β-cell relationships. Proc Natl Acad Sci USA 91: 10878-10882, 1994.
24. MacDonald MJ, Efendic S, and Ostenson CG. Normalization by insulin treatment of low mitochondrial glycerol phosphate dehydrogenase and pyruvate carboxylase in pancreatic islets of the GK rats. Diabetes 45: 886-890, 1996.
25. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, and Matsuzawa Y. PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50: 2094-2099, 2001.
26. Malaisse WJ. Metabolic signaling of insulin secretion. Diabetes Rev 4: 145-149, 1996.
27. Miyazaki Y, Matsuda M, and DeFronzo RA. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 25: 517-523, 2002.
28. Orland MJ and Permutt MA. Quantitative analysis of pancreatic proinsulin mRNA in genetically diabetic (db/db) mice. Diabetes 37: 341-347, 1987.
29. Poitout V and Robertson RP. Mini review: secondary β-cell failure in type 2 diabetes - a convergence of glucotoxicity and lipotoxicity. Endocrinology 143: 339-342, 2002.
30. Shimabukuro M, Zhou YT, Lee Y, and Unger RH. Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J Biol Chem 273: 3547-3550, 1998.
31. Shimabukuro M, Zhou YT, Levi M, and Unger KH. Fatty acid-induced β-cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci USA 95: 2498-2502, 1998.
32. Shimaya A, Kurosaki E, Nakano R, Hirayama R, Shibasaki M, and Shikama H. The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice. Metabolism 49: 411-417, 2000.
33. Taylor SI, Accili D, and Imai Y. Insulin resistance or insulin deficiency: which is the primary cause of NIDDM? Diabetes Care 43: 735-740, 1994.
34. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM: genetic and clinical implications. Diabetes 44: 863-870, 1995.
35. Yajima K, Hirose H, Fujita H, Seto Y, Fujita H, Ukeda K, Miyashita K, Kawai T, Yamamoto Y, Ogawa T, Yamada T, and Saruta T. Combination therapy with PPARγ and PPARα agonists increases glucose-stimulated insulin secretion in db/db mice. Am J Physiol Endocrinol Metab 284: E966-E971, 2003.
36. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, and Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8: 1288-1295, 2002.
37. Yki-Jarvinen H. Glucose toxicity. Endocr Rev 12: 415-431, 1992.